Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VK5211 · 1 trial · 1 indication
Efficacy of VK5211 after 12 weeks of treatment by mean placebo-corrected percentage change in total body less head (TBLH) lean body mass assessed by whole body dual-energy x-ray absorptiometry scan (DXA) scan.
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Placebo QD |
| VK5211- 0.5mg | EXPERIMENTAL | 0.5mgQD |
| VK5211- 1.0mg | EXPERIMENTAL | 1.0mg QD |
| VK5211- 2.0mg | EXPERIMENTAL | 2.0mg QD |
| Name | Type | Description |
|---|---|---|
| VK5211 | DRUG | Capsule |
| Placebo | DRUG | Capsule |
Inclusion Criteria: * Males or females ≥65 years old who are recovering from a hip fracture (occurring 3-7 weeks prior) with no residual surgical issues will be eligible for participation. Exclusion Criteria: * Pathological fracture (e.g. fracture due to Paget's disease of bone, malignancy, etc.)...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Zimmer Biomet Holdings, Inc. | ZBH | 23 | N/A | Undisclosed |
| Stryker Corporation | SYK | 4 | - | Undisclosed |
| Johnson & Johnson | JNJ | 1 | N/A | Undisclosed |
| Orthofix Medical, Inc. | OFIX | 1 | - | Undisclosed |
| Cooper Companies, Inc. | COO | 1 | - | Undisclosed |
VK5211 is an investigational small molecule being developed for the treatment of hip fractures. It is intended for patients aged 65 years or older who have experienced an acute hip fracture. The drug is currently in Phase 2 clinical development and has not yet been approved by regulatory authorities.
VK5211 is a small molecule developed by Viking Therapeutics. Its specific molecular target has not been disclosed in available information. The drug is being studied for its potential to aid in recovery from hip fractures, but the exact mechanism of action is not publicly detailed.
VK5211 is being developed by Viking Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol VKTX. The company is conducting clinical trials to evaluate the safety and efficacy of VK5211 for the treatment of hip fractures.
VK5211 is in Phase 2 clinical development. It is an investigational drug and has not received FDA approval. The Phase 2 trial for VK5211 has been completed, and the drug remains under investigation for its potential use in treating hip fractures.
VK5211 has been studied in one completed Phase 2 clinical trial with the identifier NCT02578095. This trial, titled 'Acute Hip Fracture Study in Patients 65 Years or Greater,' enrolled 108 participants and was conducted in the United States, Hungary, Romania, and Serbia.
VK5211 is the primary name for this investigational drug developed by Viking Therapeutics. No alternative names have been associated with VK5211 in available information. It is a distinct small molecule being studied for the treatment of hip fractures.